List of Adlarity drug patents

Adlarity is owned by Corium.

Adlarity contains Donepezil Hydrochloride.

Adlarity has a total of 7 drug patents out of which 0 drug patents have expired.

Adlarity was authorised for market use on 11 March, 2022.

Adlarity is available in system;transdermal dosage forms.

Adlarity can be used as a method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type.

The generics of Adlarity are possible to be released after 11 August, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016372 CORIUM Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
Jul, 2037

(14 years from now)

US11103463 CORIUM Methods for treating alzheimer's disease with donepezil transdermal system
Jul, 2037

(14 years from now)

US9993466 CORIUM Donepezil transdermal delivery system
Jul, 2037

(14 years from now)

US10300025 CORIUM Donepezil transdermal delivery system
Jul, 2037

(14 years from now)

US10307379 CORIUM Donepezil transdermal delivery system
Jul, 2037

(14 years from now)

US10835499 CORIUM Systems and methods for long term transdermal administration
May, 2038

(15 years from now)

US10966936 CORIUM Systems comprising a composite backing and methods for long term transdermal administration
Aug, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 11, 2025

Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient

Market Authorisation Date: 11 March, 2022

Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

ADLARITY family patents

33

United States

11

Japan

9

Korea, Republic of

7

Australia

6

Canada

6

China

6

European Union

3

Russia

3

Singapore

3

Mexico

1

Israel

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic